BioAtla, Inc.

BCAB

We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics ( CAB or CABs ) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$3M

EPS-$25.30

P/E-0.08

P/FCF–

EV/EBITDA-0.24

FCF Yield–

Div. Yield–

Net Debt/FCF–

BioAtla, Inc. intrinsic value

52-Week Range

$1.08$5.84

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$31M

▲ +14.6% YoY

Op. Margin

–

ROIC

-417.10%

▼ -307.5pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF

N/A

Op. Cash Flow (TTM)

-$23M

▲ +33.0% YoY

Net Debt

$4M

Cash & Equiv.

$2M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BCAB

CompareIntrinsic value

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

ATYRAtyr Pharma Inc.

$6.18-6.79%10

VIVSVivoSim Labs, Inc.

$0.15+8.71%10

PALIPalisade Bio Inc.

$1.25+1.63%20

AIMAIM ImmunoTech Inc.

$0.16+0.63%15

CRDFCardiff Oncology Inc.

$0.87+1.03%36

INMBInmune Bio Inc.

$1.33+0.76%10

BioAtla (BCAB) in three numbers

Quality score: 0/100; Best check: net debt, $4M.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -0.08; Negative: a loss over the last twelve months.; Financials

Questions about BioAtla

Is BioAtla a high-quality business?

BioAtla scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 2 checks computed from SEC filings. Its best check is net debt at $4M. The Quality tab shows every check against its target.

Does BioAtla (BCAB) pay a dividend?

No. BioAtla (BCAB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 13 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in BCAB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BCAB

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.